MiMedx Goodwill and Intangible Assets 2010-2025 | MDXG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

MiMedx goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

MiMedx goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$248.3B
Amgen (AMGN)	$155.9B
Gilead Sciences (GILD)	$142.4B
Vertex Pharmaceuticals (VRTX)	$99.3B
Bristol Myers Squibb (BMY)	$96.1B
GSK (GSK)	$81.1B
CSL (CSLLY)	$67.7B
Regeneron Pharmaceuticals (REGN)	$62.3B
Alnylam Pharmaceuticals (ALNY)	$59.1B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$27.9B
BioNTech SE (BNTX)	$25.2B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.4B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.7B
Illumina (ILMN)	$15.2B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.3B
Moderna (MRNA)	$9.6B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Bio-Techne Corp (TECH)	$8.9B
Exact Sciences (EXAS)	$8.7B
Halozyme Therapeutics (HALO)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B